Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befotertinib vs Icotinib in Advanced NSCLC with ECOG >=2
NCT07900243Phase 4Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 4 trial of befotertinib in non-small cell lung cancer (NSCLC). Planned start Nov 2026; status: not yet recruiting.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07900243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07900243.